Analysis of Investment Analysts' Outlook on Regencell Bioscience Holdings Limited and Peers

Jun 18, 2025 11:00 AM - Tony Dante

Image credit: Google Images

Regencell Bioscience Holdings Limited (NASDAQ:RGC) faces a highly pessimistic outlook from investment analysts with a target price suggesting a -99.96% difference.
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) is identified as having the highest growth potential among peers, with a target price indicating a 175.08% upside.
Other companies like Cosmos Health Inc. (NASDAQ:COSM) and Collegium Pharmaceutical, Inc. (NASDAQ:COLL) show varied growth potentials, highlighting the diverse analyst outlooks within the sector.

Regencell Bioscience Holdings Limited (NASDAQ:RGC) is a company involved in the development of traditional Chinese medicine-based treatments. Currently, RGC is trading at $610.50, but analysts have set a target price of approximately $0.22. This stark difference of -99.96% suggests a highly pessimistic outlook from investment analysts, leading to its exclusion from coverage.

In contrast, AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) is seen as having the highest growth potential among RGC's peers. AcelRx is trading at $0.86, with a target price of $2.37, indicating a price percentage difference of 175.08%. This suggests a substantial upside potential, making it an attractive option for investors seeking growth.

Cosmos Health Inc. (NASDAQ:COSM) also shows promise with a price percentage difference of 142.02%. This indicates that analysts see potential for significant growth, although not as high as AcelRx. On the other hand, Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has a negative price percentage difference of -40.44%, reflecting a less favorable outlook.

Overall, AcelRx Pharmaceuticals, Inc. stands out with the highest target price change among its peers. This indicates a more optimistic outlook from analysts compared to Regencell Bioscience Holdings Limited, which faces a challenging market perception.

Other Blogs

Nov 22, 2024 5:08 AM - Parth Sanghvi

Fundamental Analysis: Principles, Types, and How to Use It

Fundamental analysis is one of the most essential tools for investors and analysts alike, helping them assess the intrinsic value of a stock, company, or even an entire market. It focuses on the financial health and economic position of a company, often using key data such as earnings, expenses, ass...

Dec 17, 2024 8:58 AM - Sanzhi Kobzhan

Examining Tesla’s Financial Health Using FinancialModelingPrep’s Ratios API

Tesla, one of the world’s most talked-about electric vehicle manufacturers, attracts a lot of attention from investors and market watchers. By examining a snapshot of Tesla’s financial ratios—such as those provided by FinancialModelingPrep’s Ratios API—we can get a clearer picture of the company’s f...

Dec 22, 2024 7:59 AM - Sanzhi Kobzhan

Two great Software Platform Stocks Similar to Palantir (PLTR)

When it comes to cutting-edge software and data analytics, Palantir Technologies (NYSE: PLTR) is often front and center. But for many investors, it’s important to consider alternative or complementary stocks in the same sector that may offer robust growth potential. As PLTR looks expensive (overvalu...